WideCells Group PLC said CFO David Bridgland and Chief Scientific Officer Peter Hollands have stepped down from the company's board.
Both directors are stepping down as part of the company's board restructuring to minimize costs, refocus its strategy on the core operational divisions and target revenue growth.
Bridgland will remain as director until the end of 2018, while a nonboard financial controller will be recruited. Hollands will continue his role as WideCells Group's chief scientific officer and remain a director of the company's WideCells Storage and Research division.
The U.K.-based healthcare services company also said Peter Presland, the company's chairman, will take on additional responsibilities until WideCells Group has stabilized.